EUCTR2006-004495-13-AT进行中（未招募）不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 7,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For Einstein-DVT:
- •confirmed acute symptomatic proximal DVT without symptomatic PE , or
- •For Einstein-PE:
- •confirmed acute symptomatic PE with or without symptomatic DVT
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Legal lower age limitations (country specific)
- •2. Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE
- •3. Other indication for VKA than DVT and/or PE
- •4. More than 48 hours pre-randomization treatment with therapeutic dosages of anticoagulant treatment or more than a single dose of VKA prior to randomization.
- •5. Participation in another pharmacotherapeutic study within 30 days
- •6. Creatinine clearance < 30 ml/min,
- •7. Significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or ALAT > 3 x ULN
- •8. Bacterial endocarditis
- •9. Life expectancy <3 months
- •10. Active bleeding or high risk for bleeding contraindicating treatment with
- •enoxaparin or VKA
- •11. Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg
- •12. Childbearing potential without proper contraceptive measures, pregnancy or breast feeding
- •13. Any other contraindication listed in the local labeling of warfarin,
- •acenocoumarol, or enoxaparin
- •14. Concomitant use of strong CYP3A4 inhibitors (e.g., HIV protease inhibitors, systemic ketokonazole) or strong CYP3A4 inducers like rifampicin.
研究者
相似试验
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-LVBayer Healthcare AG7,465
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-DEBayer Healthcare AG7,465
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-FIBayer Healthcare AG7,400
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-SEBayer Healthcare AG7,400
已完成
3 期
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary EmbolismCTRI/2007/091/000024Bayer Healthcare AG